TY - JOUR
T1 - Practical considerations in the use of regorafenib in metastatic colorectal cancer
AU - Loupakis, Fotios
AU - Antonuzzo, Lorenzo
AU - Bachet, Jean-Baptiste
AU - Kuan, Feng-Che
AU - Macarulla, Teresa
AU - Pietrantonio, Filippo
AU - Xu, Rui-Hua
AU - Taniguchi, Hiroya
AU - Winder, Thomas
AU - Yuki, Satoshi
AU - Zeng, Shan
AU - Bekaii-Saab, Tanios
N1 - © The Author(s), 2020.
PY - 2020/10/31
Y1 - 2020/10/31
N2 - Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician-patient communication points to facilitate shared decision-making.
AB - Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician-patient communication points to facilitate shared decision-making.
U2 - 10.1177/1758835920956862
DO - 10.1177/1758835920956862
M3 - Review article
C2 - 33193826
VL - 12
SP - 1
EP - 12
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
SN - 1758-8340
ER -